Protara Therapeutics
(NASDAQ) TARA
Protara Therapeutics Financials at a Glance
Market Cap
$242.80MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Revenue (TTM)
$0.00
Net Income (TTM)
-$63.31M
EPS (TTM)
-$1.35
P/E Ratio
-3.19
Dividend
$0.00
Beta (Volatility)
1.13 (Average)
Dividend
$0.00
Beta (Volatility)
1.13 (Average)
Price
$4.32
Volume
1,008,277.985
Open
$4.22
Price
$4.32
Volume
1,008,277.985
Open
$4.22
Previous Close
$4.32
Daily Range
$4.08 - $4.37
52-Week Range
$2.97 - $7.82
Estimated Earnings Date
Aug 10, 2026
Dividend
$0.00
Beta (Volatility)
1.13 (Average)
Price
$4.32
Volume
1,008,277.985
Open
$4.22
Previous Close
$4.32
Daily Range
$4.08 - $4.37
52-Week Range
$2.97 - $7.82
Estimated Earnings Date
Aug 10, 2026
TARA News
TARA: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Protara Therapeutics
Industry
Biotechnology
Sector
Health CareEmployees
51
CEO
Jesse Shefferman, MBA
Website
www.protaratx.comHeadquarters
New York City, NY 10010, US
TARA Financials
Key Financial Metrics (TTM)
Gross Margin
0.00%
Operating Margin
0.00%
Net Income Margin
0.00%
Return on Equity
-38.70%
Return on Capital
-32.31%
Return on Assets
-32.99%
Earnings Yield
-31.35%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$242.80MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Shares Outstanding
56.20M
Volume
1.01M
Avg. Volume
749.82K
Financials (TTM)
Gross Profit
-$90.00K
Operating Income
-$70.05M
EBITDA
-$62.94M
Operating Cash Flow
-$63.00M
Capital Expenditure
-$50.00K
Free Cash Flow
-$63.05M
Cash & ST Invst.
$135.79M
Total Debt
$3.06M
Protara Therapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonCurrently no data to display.
Earnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$0.00
N/A
Gross Profit
-$90.00K
N/A
Gross Margin
0.00%
N/A
Market Cap
$242.80MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
N/A
Market Cap/Employee
$5.28M
N/A
Employees
46
N/A
Net Income
-$17.78M
-49.3%
EBITDA
-$17.69M
-49.5%
Quarterly Fundamentals
Total Cash
$135.79M
+9.2%
Total Debt
$3.06M
-27.7%
Accounts Receivable
$1.52M
+312.2%
Inventory
$0.00
N/A
Long Term Debt
$1.79M
-41.3%
Short Term Debt
$1.26M
+8.0%
Return on Assets
-32.99%
N/A
Return on Invested Capital
-38.28%
N/A
Free Cash Flow
-$21.34M
-44.6%
Operating Cash Flow
-$21.34M
-45.1%